BEIJING, Feb. 13, 2018 /PRNewswire/ -- CANbridge Life
Sciences, a biopharmaceutical company focused on developing Western
drug candidates in China and
North Asia, announced that
industry veteran, Michael Glynn, has
joined the company's advisory team, where he will provide
leadership, direction and input on the CANbridge commercial
strategy and planning as the company prepares for its first
commercial launch.
Mr. Glynn is a seasoned global executive with over 40 years of
general management and commercialization experience in Asia Pacific, Japan, the Middle
East, Latin America and
the United States. Most recently,
Mr. Glynn was Senior Vice President, Global Commercial Operations,
for Synageva BioPharma, where he managed global commercial
infrastructure development and implementation for their rare
disease lead product launch. His prior experience covers decades of
global commercial strategic, leadership and operations activities
in medical products and devices in multiple territories, including
at Genzyme Corporation, where he rose to the position of Senior
Vice President and Regional President, Japan and Asia
Pacific. While at Genzyme, Mr. Glynn directed Genzyme's
Japan-Asia Pacific business, growing $186 million in 2007 to $500 million in 2011.
Mr. Glynn also held several positions at Boston Scientific
Corporation, including President, Endovations Division, overseeing
the development and launch of a new medical device, and Vice
President and General Manager, Asia, Middle
East, Turkey, as well as
Vice President and General Manager, Asia
Pacific, where he was responsible for operations in each of
those areas. Mr. Glynn also held various executive positions
with healthcare companies in the U.S. and Asia, including the Australian subsidiary of
Baxter International, where he was involved in a variety of
strategic planning and manufacturing Management roles.
Mr. Glynn holds a Master of Business Administration from
Macquarie University, in Sydney,
Australia, and a Diploma in Education and a Bachelor of
Science, from the National University of
Ireland.
"We are delighted to bring Mike onto the advisory team at this
crucial juncture for CANbridge," said James
Xue, PhD, CANbridge Chairman, CEO and President. "His
depth-of-experience in commercial strategic planning and operations
in the Asia Pacific region, as
well as in building and managing a rapidly-growing product
portfolio, will be instrumental as we transition to a
commercial-stage company. He also brings a rich network of business
contacts in the region, which we plan to leverage as we continue to
expand."
About CANbridge Life Sciences
CANbridge Life Sciences, Ltd. is a clinical-staged
bio-pharmaceutical company accelerating development and
commercialization of specialty healthcare products for serious and
critical medical conditions in China and North
Asia (Korea and Taiwan). CANbridge develops partnerships
with Western bio-pharmaceutical companies with clinical-stage
pharmaceutical, medical device or diagnostic products that are
either unavailable in China/North
Asia or address medical needs that are underserved in the
region. CANbridge also licenses, or obtains exclusive rights to
commercialize, drug and device products that are approved in their
home markets for commercialization in China and North
Asia.
CANbridge has exclusive rights to develop and commercialize Puma
Biotechnology's NERLYNX® (neratinib) in China, Taiwan, Hong
Kong and Macao
(collectively, greater China),
which was approved by the FDA in 2017 for the extended adjuvant
treatment of adult patients with early-stage HER2-positive breast
cancer following adjuvant trastuzumab-based therapy. CANbridge
plans to target HER2-positive cancers, including breast and
gastric. CANbridge has a license with Apogenix to develop,
manufacture and commercialize immune-oncology therapy, APG101, for
the treatment of glioblastoma multiforme in China, Macao,
Hong Kong and Taiwan, where it is being developed as CAN008,
and a world-wide license (ex-North
America) with AVEO Oncology to develop, manufacture and
commercialize clinical-stage ErbB3 (HER3) inhibitory antibody
candidate AV203, renamed by CANbridge as CAN017. CANbridge also has
an agreement with EUSA Pharma to commercialize Caphosol® in
China for the prevention and
treatment of oral mucositis caused by cancer treatments.
Led and backed by a highly-seasoned executive team, with
extensive Chinese drug development experience, CANbridge has the
capability to select, acquire, develop and commercialize future
therapeutics and diagnostics targeting the unmet medical needs of
Chinese and East Asian patients with serious or critical
conditions.
CANbridge is privately-held and headquartered in Beijing, China. For more on CANbridge Life
Sciences, please go to www.canbridgepharma.com.
Contact:
CANbridge Life
Sciences
James Xue
CEO
+8610.8414.8018
781.995.0074
Media
Deanne Eagle
Planet Communications
190252@email4pr.com
917.837.5866
View original content with
multimedia:http://www.prnewswire.com/news-releases/industry-veteran-joins-canbridge-life-sciences-advisory-team-300597358.html
SOURCE CANbridge Life Sciences